Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
CARPROFEN
Chanelle Pharmaceuticals Manufacturing Limited
QM01AE91
CARPROFEN
20 Milligram
Tablets
POM
Canine
Carprofen
N.S.A.I.D
Authorised
2006-03-03
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Canidryl 20 mg Tablets for dogs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENT Carprofen 20.0 mg/tablet EXCIPIENTS For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. A plain round flat bevelled edge white tablet with a breakline on one side. The tablets can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain. 4.3 CONTRAINDICATIONS Do not use in cats. Do not use in pups less than 4 months of age. Do not use in case of hypersensitivity to active substance or to any of the excipients. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia. Refer to section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Refer to Sections 4.3 and 4.5 IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/08/2011_ _CRN 7010826_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use in aged dogs, may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. Concurrent administration of potential nephrotoxic drugs should be avoided. NSAIDs can cause inhibition of phagocytosis and hence in the treatment Lees het volledige document